Brandywine Managers LLC Invests $2.16 Million in Twist Bioscience Corporation $TWST

Brandywine Managers LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,970 shares of the company's stock, valued at approximately $2,157,000. Twist Bioscience comprises approximately 1.1% of Brandywine Managers LLC's holdings, making the stock its 10th largest holding.

Several other hedge funds have also made changes to their positions in TWST. Royal Bank of Canada grew its holdings in shares of Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company's stock worth $1,585,000 after purchasing an additional 4,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Twist Bioscience by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company's stock valued at $2,765,000 after buying an additional 3,181 shares during the period. Goldman Sachs Group Inc. grew its stake in Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company's stock worth $36,629,000 after purchasing an additional 37,577 shares in the last quarter. Intech Investment Management LLC grew its position in shares of Twist Bioscience by 18.9% during the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company's stock worth $1,135,000 after buying an additional 4,591 shares in the last quarter. Finally, Norges Bank acquired a new position in Twist Bioscience during the 2nd quarter worth approximately $737,000.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Guggenheim reissued a "buy" rating on shares of Twist Bioscience in a research report on Monday. Canaccord Genuity Group lifted their target price on Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Robert W. Baird lifted their target price on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an "outperform" rating in a report on Tuesday, August 4th. Finally, UBS Group set a $89.00 price objective on Twist Bioscience in a report on Monday, June 15th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $98.30.

Insiders Place Their Bets

In other Twist Bioscience news, insider Dennis Cho sold 14,205 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the transaction, the insider directly owned 105,141 shares in the company, valued at $9,436,404.75. This represents a 11.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of the company's stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the sale, the senior vice president owned 120,414 shares in the company, valued at approximately $10,514,550.48. This trade represents a 0.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 151,529 shares of company stock valued at $17,708,772 over the last ninety days. Insiders own 3.08% of the company's stock.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $140.80 on Tuesday. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $145.93. The firm has a 50 day moving average price of $101.89 and a 200 day moving average price of $71.16. The company has a market cap of $8.83 billion, a price-to-earnings ratio of -63.42 and a beta of 2.14. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million during the quarter, compared to analysts' expectations of $114.55 million. During the same quarter in the previous year, the business posted $0.33 EPS. The company's quarterly revenue was up 23.2% on a year-over-year basis. Sell-side analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source